We present a flexible, open source R package designed to obtain additional biological and epidemiological insights from commonly available serological datasets. Analysis of serological responses against pathogens with multiple strains such as influenza pose a specific statistical challenge because observed antibody responses measured in serological assays depend both on unobserved prior infections and the resulting cross-reactive antibody dynamics that these infections generate. We provide a general modelling framework to jointly infer these two typically confounded biological processes using antibody titres against current and historical strains. We do this by linking latent infection dynamics with a mechanistic model of antibody dynamics that generates expected antibody titres over time. This makes it possible to use observations of antibodies in serological assays to infer an individual's infection history as well as the August 8, 2019
First we outline how this expression is flexibly implemented in the serosolver 81 package, then we show how the package can be applied to cross-sectional and possible test strains. Following previous work [27] , the expected log titre individual i 89 has against the strain that circulated at time j when observed at time k is defined as a 90 linear combination of the contribution of antibody responses from each prior infection: 91
The model components are defined by: 92 1. Long-term boosting. This is defined by a parameter µ 1 , equivalent to the expected 93 persistent rise in titre against a homologous strain following primary infection. waning parameter to be fitted, and t m = k − m is the time since infection with 97 strain m. 98 3. Long-term cross-reactive antibody response from related strains. We assume the 99 level of cross-reaction between a test strain j and infecting strain m ∈ Z i 100 decreases linearly with antigenic distance (see Data section below for definition). 101
The cross-reaction function is d 1 (j, m) = max{0, 1 − σ 1 δ m,j }, where δ m,j is 102 antigenic distance between strains j and m, and σ 1 is a fitted parameter.
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Serosolver includes an additional option to include strain-specific measurement bias, 136 which may arise through strain-specific differences in assay reactivity [26, [30] [31] [32] .
137
Specifically, an additional observation error is added to the predicted log antibody titres; 138 this measurement error can be different for each individuals strain or can be specified 139 for a group (or cluster) of strains. The predicted titre X i,j,k taking into account 140 strain-specific measurement bias is given as:
Where χ j is the measurement offset for strain j. The hierarchical form of the 142 measurement bias term may also be specified by the user: χ j may be estimated as an 143 independent parameter for each j; may be assumed to come from a hierarchical 144 distribution χ j ∼ N (χ, σ 2 χ ); and may be fixed for particular strains/groups e.g., fixing 145 histories for the sample population are therefore described by a binary matrix, Z, where 151 each row represents an individual, i, and each column represents a time, j, at which an 152 individual could be infected once. The probability of the infection history matrix, P (Z) 153 is given by,
Each infection event (Z i,j ) is the outcome of a single Bernoulli trial, with probability 155
The choice of the prior distribution for the probability of 156 infection, P (φ j ), is discussed below and in further detail in Supplementary Material 1. 157
The time resolution of infection times may be set by the user depending on the data; The initial development of serosolver focused on influenza A/H3N2, which has 173 circulated in human populations since 1968 and has undergone substantial antigenic 174 evolution over this time [23, [32] [33] [34] . Figure 1 illustrates how our analytical approach 175 applies to influenza A/H3N2. In this case, we make the assumption that the antigenic 176 distance between strains can be described by a two-dimensional distance, with strains 177 moving through the space over time. The expected log antibody titre for a given 178 individual against a specific strain at a specific time can therefore be predicted using Conceptual overview of the analytical approach used in serosolver, as applied to influenza A/H3N2. Top panel: antigenic map for influenza A/H3N2 using coordinates from [23] , with different viruses coloured by year of isolation. Solid points show centroids across all strains isolated in a given year, hollow points show individual strains. Dashed line shows an antigenic summary path, generated by fitting a smoothing spline through the observed isolates. Points further apart in space are less cross-reactive. Middle panel: conceptual illustration of the antibody kinetics model. An individual is infected with the orange virus, which results in boosting and waning of homologous antibody titres. In parallel, antibodies that cross react with viruses at different points in antigenic space also boost and wane (green and blue viruses). The individual is later infected by the green virus, which leads to further boosting and waning of antibodies. Bottom panel: HI titres measured from serum samples taken at different times capture different parts of the homologous and cross reactive antibody kinetics. Different sampling strategies will represent different subsets of these measurements e.g., a cross-sectional study might inform a single subplot, whereas a longitudinal study might inform just the orange bars from each of the three subplots. Clearly a sampling strategy with multiple serum samples and many viruses tested per sample will provide the most information.
August 8, 2019 9/30 could have been infected based on the earliest and latest circulating strains in the 190 antigenic map.
191
The second dataset consists of individual-level log titres against one or more viruses 192 defined in the antigenic map. Each titre measurement is accompanied by a sampling 193 time k (i.e., when the serum sample was collected) and strain circulation time j (i.e.,
194
when the strain was originally isolated). structures that are not well characterised by standard prior assumptions (i.e., highly 216 dispersed attack rates and variation in individual-level susceptibility) [35] . We therefore 217 provide the user with flexibility in the assumed infection history and attack rate priors, 218
with different prior assumptions each bringing their own biases and rationale.
Serosolver includes four infection history prior options. We summarise these priors in 220
the main text, though an extensive discussion is provided in Supplementary Material 1. 221
Hyper-prior on the probability of infection over time, version 1: Under 222 this prior, the probability of infection is given by φ j . The infection generating process is: 223
where f is a user specified function describing the prior distribution on φ, P (φ j ). By 224 default, f is the uniform distribution, φ j ∼ unif (0, 1), though it may be set to integrating over values for φ, each φ need not be estimated explicitly. We have found 231 that this improves convergence of the model fitting framework. The infection generating 232 process is:
The probability of infection in a given time period is independent of other time Rather, a prior is placed on the total number of infections that an individual is expected 242
to experience over the course of their life. This is the prior used in our previous
The prior on the per-capita attack rate across all individuals therefore follows a 245 binomial distribution, and the prior on the lifetime number of infections for any 246 individual follows a beta-binomial distribution, with parameters α and β that can be set 247 by the user. 
This assumption places a beta-binomial prior on both the number of infections at a Furthermore, although much of the development of this package came from analysis of 293 influenza A/H3N2 dynamics, these concepts and inputs are easily adaptable to antigenically stable pathogens by specifying the input antigenic map.
295
The package work flow is divided into a number of distinct stages, which handle the 296 data and parameter inputs, simulation, inference, posterior diagnostics, and analysis 297 (Fig 2) We developed the package to rely on only a few function calls for each of these 298 stages, but with ample room for customisation and flexibility at each stage.
299
To set up the model, users only need to provide: a data frame describing the model 300 parameters (they can also change a flag to fix or estimate any of the parameters); a chains may be run in parallel locally, but we note that much of our own work with 321 serosolver is done using a high performance cluster. Inputs and outputs for the serosolver R package. The package has two sets of inputs to define data and parameters. These feed into the process model that can either be used to simulate data by itself, or combined with observed data and MCMC to obtain three posterior outputs: individual-level infection histories, population probability of infection, and biological parameters. Once these posteriors have been obtained, serosolver can run MCMC diagnostics and plot key immunological and epidemiological processes The second case study considers cross-sectional serological samples collected in southern 376
China in 2009, which were tested against nine historical influenza A/H3N2 strains that 377 circulated between 1968 and 2008 [29, 42] . Serosolver can be used to reconstruct shows substantial variation in the inferred historical attack rates of A/H3N2, with clear 380 periods of high incidence interspersed by periods of very low incidence (range of 381 posterior medians: 3.63% to 95.2%). In these analysis, we used a weakly informative 382 prior on the annual attack rate with a mode of 15% with prior version 2. Our posterior 383 estimates were very similar to this, with a median inferred attack rate of 14.6%, 384 suggesting either agreement between the data and prior or a lack of information in the 385 data. We also identified clear age-specific patterns of infection. Fig 5D shows These results agree with previous analyses that individuals are infected, or at least 388 experience antibody boosting, less frequently as they get older [27] . Fig 5E shows 
